Alisertib (MLN8237)

製品コードS1133

Alisertib (MLN8237)化学構造

分子量(MW):518.92

Alisertib (MLN8237)は一種の選択性オーロラ(Aurora )A阻害剤で、無細胞試験でIC50値が1.2 nMです。Alisertib (MLN8237)はオーロラAに作用する選択性はオーロラ Bに作用する選択性より200倍以上が高くなります。臨床3期。

サイズ 価格 在庫  
USD 211 あり
USD 151 あり
USD 264 あり
USD 844 あり

文献中の引用(48)

カスタマーフィードバック(12)

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

製品安全説明書

Aurora Kinase阻害剤の選択性比較

生物活性

製品説明 Alisertib (MLN8237)は一種の選択性オーロラ(Aurora )A阻害剤で、無細胞試験でIC50値が1.2 nMです。Alisertib (MLN8237)はオーロラAに作用する選択性はオーロラ Bに作用する選択性より200倍以上が高くなります。臨床3期。
特性 First orally available inhibitor of Aurora A.
靶点
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
In vitro試験

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rMTFAvPSEQvF2= NGXJXoQ4OiCq NXLYcldOTE2VTx?= M173[WlEPTB;MD6wOEDPxE1? NYKyZpByOjZzM{[2PFQ>
LS174T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMlUh|ryP NUPndIN1PzJiaB?= NV7VTZRUTE2VTx?= M3PpW2lEPTB;MD6wOUDPxE1? NX7NPY9JOjZzM{[2PFQ>
T84 NEP6bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nU[FAvPSEQvF2= MmLyO|IhcA>? MYnEUXNQ NUjLR49VUUN3ME2wMlA6KM7:TR?= NH\CTVgzPjF|Nk[4OC=>
LS180 NXjOTVN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorhNE42KM7:TR?= MnPiO|IhcA>? NH7kSnRFVVOR NXfKRmxZUUN3ME2xJO69VQ>? MYqyOlE{PjZ6NB?=
SW948 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDPNE42KM7:TR?= NIXub3M4OiCq MljZSG1UVw>? Mn3YTWM2OD1zIN88US=> NEjC[|QzPjF|Nk[4OC=>
HCT15 NVrvSGZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW1PVYxNjVizszN M4\HNFczKGh? MWfEUXNQ M2PCT2lEPTB:MD60JO69VQ>? NVjMUIRIOjZzM{[2PFQ>
DLD-1 NIDGNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorMNE42KM7:TR?= MmizO|IhcA>? MV;EUXNQ MUjJR|UxRDBwODFOwG0> NGP5UXIzPjF|Nk[4OC=>
MIP-101 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzrbGdCOC53IN88US=> NF;6OWs4OiCq M2\UU2ROW09? M{HRXWlEPTB;MTFOwG0> NIDIXJMzPjF|Nk[4OC=>
SNU1544 M{DSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;DNE42KM7:TR?= NFLqW5Q4OiCq NXjSVWJVTE2VTx?= MUHJR|UxRTFizszN NEjUWJIzPjF|Nk[4OC=>
OCI-Ly10 NG\TTHZEgXSxdH;4bYMhSXO|YYm= M1HJOVczKGh? MlLNSG1UVw>? NEHjcWhKSzVyPUCuNFU5KM7:TR?= M3vW[|I2QDd6M{Ox
SU-DHL2 MnjoR5l1d3SxeHnjJGF{e2G7 NFro[ZA4OiCq NVLUXW5STE2VTx?= M1nKSmlEPTB;MD6wNUDPxE1? NYWwUYF4OjV6N{izN|E>
OCI-LY7 Mn\uR5l1d3SxeHnjJGF{e2G7 M3rjS|czKGh? NHjQRYZFVVOR MVjJR|UxRTBwMEixJO69VQ>? Ml;FNlU5Pzh|M{G=
SU-DHL6 NVjvRWw6S3m2b4TvfIlkKEG|c3H5 M{LkNlczKGh? MUjEUXNQ NVz0fYgyUUN3ME2wMlQ5OiEQvF2= MYSyOVg4QDN|MR?=
Jeko-1 MV3DfZRwfG:6aXOgRZN{[Xl? M{\JfFczKGh? NVHqToJJTE2VTx?= M37PXWlEPTB;MD6wNlkh|ryP MUeyOVg4QDN|MR?=
JVM-2 NX\HOlNJS3m2b4TvfIlkKEG|c3H5 NHX2PFk4OiCq NH7I[VhFVVOR NITTfmZKSzVyPUCuNFEh|ryP MYGyOVg4QDN|MR?=
Rec-1 MnfxR5l1d3SxeHnjJGF{e2G7 MnrSO|IhcA>? M1XqUWROW09? MnfpTWM2OD1yLkC4O{DPxE1? NH7GXoczPTh5OEOzNS=>
Z-138 NHm3UnREgXSxdH;4bYMhSXO|YYm= NIXVfYk4OiCq MmrRSG1UVw>? NUDjV2dJUUN3ME2wMlAyOyEQvF2= M{jQS|I2QDd6M{Ox
H9 M2rpbmN6fG:2b4jpZ{BCe3OjeR?= Mk\WO|IhcA>? M2TScWROW09? NHTRSY5KSzVyPUCuOkDPxE1? NYjlSZhKOjV6N{izN|E>
HH MYnDfZRwfG:6aXOgRZN{[Xl? MofHO|IhcA>? NXLP[HQ5TE2VTx?= M{W1[mlEPTB;MD63JO69VQ>? M1TjPVI2QDd6M{Ox
DND41 NVzHU4lPS3m2b4TvfIlkKEG|c3H5 NYDSN2hRPzJiaB?= MUTEUXNQ MUPJR|UxRTBwMTFOwG0> NXvKPW5DOjV6N{izN|E>
CCL119 NEXCVmtEgXSxdH;4bYMhSXO|YYm= MXK3NkBp MXrEUXNQ NGfG[ZdKSzVyPUCuNFYzKM7:TR?= MnXzNlU5Pzh|M{G=
J.Cam 1.6 MoP0R5l1d3SxeHnjJGF{e2G7 M1rzfFczKGh? M2XaN2ROW09? M2rSc2lEPTB;MD6xNFUh|ryP NWXVUHI{OjV6N{izN|E>
Sup-T1 MU\DfZRwfG:6aXOgRZN{[Xl? MnewO|IhcA>? NELrNJNFVVOR NEXpWXhKSzVyPUKuNVQzKM7:TR?= MUCyOVg4QDN|MR?=
Tib 152 MknzR5l1d3SxeHnjJGF{e2G7 NWewTIp4PzJiaB?= MlPSSG1UVw>? MnuwTWM2OD1yLkig{txO MmDkNlU5Pzh|M{G=
MCF7 MWXGeY5kfGmxbjDBd5NigQ>? M4XlVVUh|ryP M{XpVVI1KGh? Mn\5SG1UVw>? MXrJcoR2[2W|IFeyM20h[XK{ZYP0 NIHDcI4zPTh|NESwNS=>
MDA-MB-231 M{PsXmZ2dmO2aX;uJGF{e2G7 NHXRdVM2KM7:TR?= Moq1NlQhcA>? M2XjU2ROW09? Mln1TY5lfWOnczDHN{9OKGG{cnXzeC=> NHTIcG0zPTh|NESwNS=>
MCF7 NVjWN2o6TnWwY4Tpc44hSXO|YYm= M{PaR|Uh|ryP NWrmRXhoOjRiaB?= M3vyeGROW09? MXHE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ MWWyOVg{PDRyMR?=
MCF7 MUfGeY5kfGmxbjDBd5NigQ>? NVHST41nPSEQvF2= MWiyOEBp NUnzO2F6TE2VTx?= MlP6SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> M2HuVlI2QDN2NECx
MCF7 NHT1[2RHfW6ldHnvckBCe3OjeR?= NFHReIE2KM7:TR?= NInvOmQzPCCq M1LmVGROW09? NGXyVplF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NIr0WFkzPTh|NESwNS=>
MCF7 MV;GeY5kfGmxbjDBd5NigQ>? MUC1JO69VQ>? M2XyOVI1KGh? MYHEUXNQ MUDJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> M3nrc|I2QDN2NECx
MCF7 Mn3GSpVv[3Srb36gRZN{[Xl? MXu1JO69VQ>? M1m1c|I1KGh? NFexfY1FVVOR M4nlbGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= M1LWWFI2QDN2NECx
MDA-MB-231 NVO2XWExTnWwY4Tpc44hSXO|YYm= MlzaOUDPxE1? NVnqVJVsOjRiaB?= NHHNbZNFVVOR NV\hOIJiTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> MYeyOVg{PDRyMR?=
MDA-MB-231 NYjKc3NiTnWwY4Tpc44hSXO|YYm= NHzBdoUyKM7:TR?= M3nyb|I1KGh? NEjUSVJFVVOR M2HBZmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz M3uxVlI2QDN2NECx
MDA-MB-231 M{HzeGZ2dmO2aX;uJGF{e2G7 MnOzOUDPxE1? MmizNlQhcA>? NHT5emxFVVOR MX;E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz M4jSflI2QDN2NECx
MDA-MB-231 M3jEeGZ2dmO2aX;uJGF{e2G7 NFz1[ow2KM7:TR?= NHHReZMzPCCq MlXPSG1UVw>? NXntPXpuUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? MlHXNlU5OzR2MEG=
MDA-MB-231 MXTGeY5kfGmxbjDBd5NigQ>? MWm1JO69VQ>? MmT4NlQhcA>? MoK0SG1UVw>? MYTJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? NUn1S4VHOjV6M{S0NFE>
MDA-MB-231 M{XRSmZ2dmO2aX;uJGF{e2G7 NXTIOWRzPSEQvF2= MVOyOEBp NWDzSYd2TE2VTx?= NYnDWo9HUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? NXTuRZlGOjV6M{S0NFE>
MCF7 NFmwVmRCeG:ydH;zbZMhSXO|YYm= M37CWVUh|ryP MX6yOEBp MUjEUXNQ MoLCTY5lfWOnczDhdI9xfG:2aXOg[IVifGh? Mon5NlU5OzR2MEG=
MDA-MB-231 M3LaN2Fxd3C2b4Ppd{BCe3OjeR?= NInFfIY2KM7:TR?= NXnMO4s3OjRiaB?= MX3EUXNQ MkDZTY5lfWOnczDhdI9xfG:2aXOg[IVifGh? MlvRNlU5OzR2MEG=
MCF7 NXjoZ2pvTnWwY4Tpc44hSXO|YYm= NFO2b3oyKM7:TR?= M4DsT|czKGh? MljxSG1UVw>? MojsTY5lfWOnczDheZRweGijZ3njJIRm[XSq M2HhZlI2QDN2NECx
MDA-MB-231 M1HTSWZ2dmO2aX;uJGF{e2G7 MYGxJO69VQ>? MkTXO|IhcA>? MX3EUXNQ NHmzdlFKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= MY[yOVg{PDRyMR?=
U-2 OS NX\GOYFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3WFUxKM7:TR?= M4fGSVI1KGh? M1nOV2ROW09? NHHoTHVKSzVyPUG2MlYh|ryP MmnENlU4QTJ6MUG=
MG-63 NIf4TlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e1blUxKM7:TR?= MWKyOEBp MlzYSG1UVw>? M1vLbGlEPTB;OT61JO69VQ>? MlvrNlU4QTJ6MUG=
U-2 OS NG\CZVdCeG:ydH;zbZMhSXO|YYm= MVS1JO69VQ>? Mn7MNlQhcA>? MWLEUXNQ MnKwTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NYTLO|BvOjV5OUK4NVE>
MG-63 MnXjRZBweHSxc3nzJGF{e2G7 NV22VXMyPSEQvF2= NXnmTmJxOjRiaB?= NGTpNXNFVVOR MoPJTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> MoXNNlU4QTJ6MUG=
U-2 OS M2L6PGZ2dmO2aX;uJGF{e2G7 NUjhfWV7PSEQvF2= M3jHVFI1KGh? M2TB[mROW09? M2LabXBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NXS5WIdLOjV5OUK4NVE>
MG-63 NVzr[ndqTnWwY4Tpc44hSXO|YYm= NH2zVIs2KM7:TR?= M2\kcVI1KGh? NUS1eZp[TE2VTx?= NUn2WpNTWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MmDYNlU4QTJ6MUG=
PANC-1 M3vDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK1NEDPxE1? MlPjNlQhcA>? NX;lZ5R7TE2VTx?= NWnqTWVEUUN3ME23MlEh|ryP M1zve|I2PjN{MkK1
BxPC-3 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG4e3J5PTBizszN NF:wdGwzPCCq NEPob2hFVVOR M1HPOWlEPTB;Nj64JO69VQ>? NF;Z[|YzPTZ|MkKyOS=>
PANC-1 M{DHS2Z2dmO2aX;uJGF{e2G7 Mlm2OUDPxE1? M{fQN|I1KGh? NWHLbGVyTE2VTx?= NV7XNWZDUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn NGPafGMzPTZ|MkKyOS=>
BxPC-3 MWXGeY5kfGmxbjDBd5NigQ>? M3O0blUh|ryP NF7rd2czPCCq M1fZUmROW09? NYi3NW5bUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MkLaNlU3OzJ{MkW=
PANC-1 NUDYW|YyTnWwY4Tpc44hSXO|YYm= M3j6b|Uh|ryP M2LaZlI1KGh? M1nlT2ROW09? NUTZ[Y1VUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MkK0NlU3OzJ{MkW=
BxPC-3 NV[2SIl7TnWwY4Tpc44hSXO|YYm= NILaXHM2KM7:TR?= MY[yOEBp NHP0[XNFVVOR MXrJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> Mn;CNlU3OzJ{MkW=
SKOV3 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX6dHAyODBizszN NGfteVczPCCq MkGxSG1UVw>? NVrxWlZtUUN3ME2yNE41QCEQvF2= NYqxSmw6OjV4MkS3OVA>
OVCAR4 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mxWVExOCEQvF2= MXOyOEBp NHLkVG9FVVOR MUPJR|UxRTJ{LkGzJO69VQ>? MmW5NlU3OjR5NUC=
SKOV3 NU\Dfm56TnWwY4Tpc44hSXO|YYm= M1G0fFUh|ryP NWm0b|F{PzJiaB?= M2DmNmROW09? NEfhc2tKdmS3Y3XzJGczN01iYYLy[ZN1 M37hVFI2PjJ2N{Ww
OVCAR4 NXHC[WtYTnWwY4Tpc44hSXO|YYm= MYq1JO69VQ>? NUjhOo5NPzJiaB?= M2XOdWROW09? MY\JcoR2[2W|IFeyM20h[XK{ZYP0 NGjJb3czPTZ{NEe1NC=>
SKOV3 NWLleWNoSXCxcITvd4l{KEG|c3H5 NWOxPWNRPSEQvF2= M3LJelI1KGh? MV;EUXNQ MlKxTY5lfWOnczDhdI9xfG:|aYO= NHOzbGkzPTZ{NEe1NC=>
OVCAR4 NUW0VWhTSXCxcITvd4l{KEG|c3H5 MWi1JO69VQ>? M2mxb|I1KGh? Mm\RSG1UVw>? NX31cFB4UW6mdXPld{BieG:ydH;zbZM> MW[yOVYzPDd3MB?=
AGS NGjHepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PLdVI2KM7:TR?= NHHQb3EzPCCq NHe1eI1FVVOR M2DWV2lEPTB;MUmuNFkh|ryP NGS3WpYzPTZyOUmyNy=>
NCI-N78 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W5Z|I2KM7:TR?= NXexTmlyOjRiaB?= NHT2bXhFVVOR NYDFeHlJUUN3ME2yOk4{OyEQvF2= MlLZNlU3ODl7MkO=
AGS MYDBdI9xfG:|aYOgRZN{[Xl? MYq1JO69VQ>? NFrDbIUzPCCq NELP[4VFVVOR M{XrWmlv\HWlZYOgZZBweHSxc3nz NELrdJYzPTZyOUmyNy=>
NCI-N78 M3\CUGFxd3C2b4Ppd{BCe3OjeR?= NGWwS4I2KM7:TR?= NIX6XYozPCCq M2jKOmROW09? MYrJcoR2[2W|IHHwc5B1d3Orcx?= MnP4NlU3ODl7MkO=
AGS M4LNfmZ2dmO2aX;uJGF{e2G7 NVzXflQ1PSEQvF2= NHzCUpAzPCCq M{[zVmROW09? NXfqcY1GUW6mdXPld{B1cGViYYX0c5Bp[We7 M2TGOVI2PjB7OUKz
NCI-N78 NXHxZ5FYTnWwY4Tpc44hSXO|YYm= Mo\oOUDPxE1? MX6yOEBp M4e0V2ROW09? MlnkTY5lfWOnczD0bIUh[XW2b4DoZYd6 NYjWN20xOjV4MEm5NlM>
HSC-3 NGW4XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDKNUDPxE1? NX\TS5NnPDhiaB?= MYTJR|UxRTBwNUSg{txO NXm1RXN4OjV|Nk[xOFM>
GB30 NV30UlJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHtV3cyKM7:TR?= NXvyOXJiPyCm M3G5T2ROW09? NFvwRpdKSzVyPUCuNFEyKM7:TR?= M2HzcFI2OTB4NEK4
GB9 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPESVE2OSEQvF2= M4Dyc|ch\A>? MX;EUXNQ MULJR|UxRTBwMEK0JO69VQ>? MXmyOVExPjR{OB?=
GB169 NXfWcI96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxJO69VQ>? NF\rVnQ4KGR? NFS0TIVFVVOR M{e1RmlEPTB;MD6wN|Ih|ryP NHq4fpczPTFyNkSyPC=>
T24 M2TrO2Z2dmO2aX;uJGF{e2G7 NV\meHpEOSEQvF2= NFfiUVU1QCCq NIHB[3hFVVOR NITlOIhKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 M4DjPFI{PDB|NkOz
RT4 NUK5XJU3TnWwY4Tpc44hSXO|YYm= NU\w[3RuOSEQvF2= Mo\YOFghcA>? NILNV25FVVOR M3Xnemlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MWSyN|QxOzZ|Mx?=
UM-UC-3 MkTKSpVv[3Srb36gRZN{[Xl? M3rlRlEh|ryP NWf5NoxWPDhiaB?= NX2yO2IxTE2VTx?= MVjJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MlTXNlM1ODN4M{O=
T24 NXzNRnVySXCxcITvd4l{KEG|c3H5 NFLsWZM{NjF4IN88US=> MkHWPVYhcA>? MVnEUXNQ NFnKWHVKSzVyPUCuNFMxPiEQvF2= NHXSWW8zOzRyM{[zNy=>
RT4 Ml7XRZBweHSxc3nzJGF{e2G7 MkLRN{4yPiEQvF2= MojGPVYhcA>? M4rWNWROW09? Ml;YTWM2OD1yLkGxPVgh|ryP NX7Fc2liOjN2MEO2N|M>
UM-UC-3 MULBdI9xfG:|aYOgRZN{[Xl? NXHJc29nOy5zNjFOwG0> M{[3Zlk3KGh? NWjNeFdnTE2VTx?= NXjyUXZoUUN3ME2wMlA1PDlizszN Mn7jNlM1ODN4M{O=
OVCAR-5 NIfvWopHfW6ldHnvckBCe3OjeR?= MlHNOVAhdk1? NWrEZY1uUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NGCxRZQzOzN|NEOyOy=>
SKOV3ip2 M2PudWZ2dmO2aX;uJGF{e2G7 NHLxfYI2OCCwTR?= NF\1d3hKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= NV3VdFlOOjN|M{SzNlc>
S462 NULScG5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixNFAh|ryP NEnnd2Y4OiCq MVfEUXNQ MnLBRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NEmweXQzOzN{OEGxOC=>
2884 M4XJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XvNVExOCEQvF2= NYrC[otmPzJiaB?= MWLEUXNQ M1uxdWF1fGWwdXH0[ZMh[2WubDDndo94fGh? Mn3CNlM{OjhzMUS=
2885 NWT4RYRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\seohPOTByIN88US=> MVG3NkBp NG\pN5pFVVOR M2LsfGF1fGWwdXH0[ZMh[2WubDDndo94fGh? NGmw[VMzOzN{OEGxOC=>
CRL-2396 M1y0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni5NVAxKM7:TR?= NILObWN4[XSnch?= NHLVPJZKSzVyPUCuNFkzKM7:TR?= NWrrfnNlOjNzNUO1NlQ>
TIB-48 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLCTI9YOTByIN88US=> M1L4WZdifGW{ NIjlXZRKSzVyPUCuNFg5KM7:TR?= MVmyN|E2OzV{NB?=
CRL-2396 NE\VeWdEgXSxdH;4bYMhSXO|YYm= M4rxPVEh|ryP NVrDclVJPDhiaB?= Mn3Ye4F1\XJ? MV;JcoR2[2W|IHHwc5B1d3Orcx?= MoCxNlMyPTN3MkS=
TIB-48 NWLBS3dtS3m2b4TvfIlkKEG|c3H5 NUXoe456OSEQvF2= MmKxOFghcA>? NX\afWRlf2G2ZYK= NIjxXo9KdmS3Y3XzJIFxd3C2b4Ppdy=> MWiyN|E2OzV{NB?=
AGS M37aRmN6fG:2b4jpZ{BCe3OjeR?= MWmwMlUh|ryP NGnVZW0zPCCq MoPISG1UVw>? NE\1TJNF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= NWTjdYF6OjJ7N{K2NVE>
FLO-1 NILWNHhEgXSxdH;4bYMhSXO|YYm= NWTSNmxOOC53IN88US=> NGG0U3czPCCq MX;EUXNQ NFX0UXhF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= MlfCNlI6PzJ4MUG=
OE33 MorhR5l1d3SxeHnjJGF{e2G7 M3PGV|AvPSEQvF2= MoDONlQhcA>? MXrEUXNQ M2rmRWRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu NWPwb25jOjJ7N{K2NVE>
SKLMS NXfjSXF6S3m2b4TvfIlkKEG|c3H5 NGDWWZc4PSCwTR?= M163e|k3KGh? NWDNVJhmUW6mdXPld{BieG:ydH;zbZM> MknqNlI5OjF7OUe=
Leio285 MljOR5l1d3SxeHnjJGF{e2G7 NITISIw4PSCwTR?= NYX2O3ZiQTZiaB?= NWqxR3psUW6mdXPld{BieG:ydH;zbZM> M33ISlIzQDJzOUm3
Mes-Sa MkTPR5l1d3SxeHnjJGF{e2G7 MlPnO|Uhdk1? NYnsVJQ2QTZiaB?= MUfJcoR2[2W|IHHwc5B1d3Orcx?= MYqyNlgzOTl7Nx?=
DAOY Mly3R5l1d3SxeHnjJGF{e2G7 M4SyZVExKM7:TR?= NX\sNpozPzJiaB?= MmDQSG1UVw>? M2PKb2lEPTB;MD6wOEDPxE1? M4rJSlIzPjZ7M{O1
IMR32 MYDDfZRwfG:6aXOgRZN{[Xl? NG\Id2gyOCEQvF2= M1LrU|czKGh? NHPJeFNFVVOR M2e1b2lEPTB;MD6wN{DPxE1? MljSNlI3Pjl|M{W=
Molt-4 MmDiR5l1d3SxeHnjJGF{e2G7 MVexNEDPxE1? NYH2Tpg6PzJiaB?= MVTEUXNQ NV;5SWw{UUN3ME2wMlAzKM7:TR?= M1\UOlIzPjZ7M{O1
MOLM-13 NFziV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HPblMh|ryP MWO3NkBp NGfRfHpFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MV[yNlQ5QDJ2OR?=
HL-60 M{WzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmzJO69VQ>? NEjiT4I4OiCq Mn\wSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MkjQNlI1QDh{NEm=
MV4-11 NWTYTmxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLwdWxLOyEQvF2= Mk\wO|IhcA>? NIfpW|lFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NVzKXVBTOjJ2OEiyOFk>
SKM-1 NIXBUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;QVXU{KM7:TR?= MUS3NkBp NGXQfG5FcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 Ml3FNlI1QDh{NEm=
SH2 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnuVWU3OyEQvF2= NGrTc|Q4OiCq MkCySIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NUXxSnI2OjJ2OEiyOFk>
NOMO-1 M17FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7mOZdWOyEQvF2= MXS3NkBp MWrEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NU\YVGFwOjJ2OEiyOFk>
OCL-AML2 M2jDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrsT2JDOyEQvF2= MU[3NkBp MnW1SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MmnsNlI1QDh{NEm=
PL-21 M1LDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf6NXc{KM7:TR?= MmPTO|IhcA>? Mn63SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M1z5WFIzPDh6MkS5
KG-1 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuxe4Q{KM7:TR?= Mmq5O|IhcA>? MmfnSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M4[yXFIzPDh6MkS5
A172 M2HoeGN6fG:2b4jpZ{BCe3OjeR?= NGjwdXMyODBizszN M4W5WlI1KGh? MlLaSG1UVw>? NHHXSItKSzVyPUCuNVIxKM7:TR?= MXmyNlI4PDN7OR?=
U87 M13WPWN6fG:2b4jpZ{BCe3OjeR?= NXrnUZlqOTByIN88US=> NELONHozPCCq NW\LfYJ[TE2VTx?= M2PPZmlEPTB;MD6xNFUh|ryP NESybHozOjJ5NEO5PS=>
U251 MUjDfZRwfG:6aXOgRZN{[Xl? NHy2XHAyODBizszN NHnDc|czPCCq MX\EUXNQ NVXLPVZkUUN3ME2wMlExOCEQvF2= MlHyNlIzPzR|OUm=
T98 M1\UemN6fG:2b4jpZ{BCe3OjeR?= MVyxNFAh|ryP MkDxNlQhcA>? NUnBO4dKTE2VTx?= MmX0TWM2OD1yLkGyOUDPxE1? MnuxNlIzPzR|OUm=
LN18 NWruUm5NS3m2b4TvfIlkKEG|c3H5 NX2ye|M5OTByIN88US=> NXLMNnBMOjRiaB?= NF;ORolFVVOR M4HIb2lEPTB;MD6yNVAh|ryP M1yzTFIzOjd2M{m5
LN443 NGfYZVlEgXSxdH;4bYMhSXO|YYm= NXX5UpF7OTByIN88US=> M{jrN|I1KGh? MknXSG1UVw>? Mkm0TWM2OD1yLkKyNEDPxE1? MmTnNlIzPzR|OUm=
HF66 NWXt[|dUS3m2b4TvfIlkKEG|c3H5 NYPRTm9zOTByIN88US=> NIXaTYEzPCCq NVzGfplpTE2VTx?= MWTJR|UxRTBwMkK1JO69VQ>? NVTOSJRrOjJ{N{SzPVk>
HF2303 NWKyRXdOS3m2b4TvfIlkKEG|c3H5 M3[xOVExOCEQvF2= M4jtUFI1KGh? Mlm0SG1UVw>? MVfJR|UxRTBwME[wJO69VQ>? M1X1U|IzOjd2M{m5
HF2359 MVvDfZRwfG:6aXOgRZN{[Xl? MonUNVAxKM7:TR?= Mn\0NlQhcA>? MkT3SG1UVw>? NInhcmZKSzVyPUCuNFYxKM7:TR?= MYmyNlI4PDN7OR?=
HF2414 M3PhVGN6fG:2b4jpZ{BCe3OjeR?= NV;wOnVKOTByIN88US=> NYnxT5JyOjRiaB?= NInHWG5FVVOR MXfJR|UxRTBwMEiwJO69VQ>? NInnNVEzOjJ5NEO5PS=>
A-673 M2PzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nT[|ExKM7:TR?= MVm5OkBp MkXDSG1UVw>? NIL1VoZKSzVyPUCuNFMzKM7:TR?= NYDtXY5tOjF2NEi1PVE>
TC-32 NH7QUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fneVExKM7:TR?= MXW5OkBp MlvuSG1UVw>? MX\JR|UxRTBwMEO5JO69VQ>? NYr1cFg4OjF2NEi1PVE>
TC-71 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnUNVAh|ryP MWq5OkBp NUnURYlvTE2VTx?= Mn\GTWM2OD1yLkGwNkDPxE1? M3TFcFIyPDR6NUmx
SK-N-MC NFTBeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3OV3VjOTBizszN NF7KWow6PiCq NXHKXIl1TE2VTx?= MlnKTWM2OD1yLkC3NkDPxE1? MXOyNVQ1QDV7MR?=
CHLA-9 NEfDclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXNNVAh|ryP MVi5OkBp NEK2Zo1FVVOR NV\4[2VLUUN3ME2wMlAyQCEQvF2= MlH3NlE1PDh3OUG=
CHLA-10 NEPseYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fKNFExKM7:TR?= M324[|k3KGh? MXfEUXNQ M2GwOGlEPTB;MD6wOlAh|ryP NXPnfoJ2OjF2NEi1PVE>
CHLA-25 NGrud4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP0Spd1OTBizszN Ml7SPVYhcA>? NEj2[mlFVVOR NFPZfXZKSzVyPUCuNVY5KM7:TR?= MVWyNVQ1QDV7MR?=
CHLA-32 NXvnOIhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7kd|MyOCEQvF2= MkTXPVYhcA>? NH\GenlFVVOR MkW0TWM2OD1yLkGzOkDPxE1? MoPlNlE1PDh3OUG=
CHLA-56 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDuSoMyOCEQvF2= Mlu4PVYhcA>? M{DVO2ROW09? NIfUWGVKSzVyPUGwJO69VQ>? NUnUZ|kyOjF2NEi1PVE>
CHLA-258 M2LzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT4NVAh|ryP NYmycJV7QTZiaB?= M3PzZ2ROW09? MWfJR|UxRTBwMUOyJO69VQ>? MV:yNVQ1QDV7MR?=
COG-E-352 NX;4fpZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xNEDPxE1? NWDmR3l2QTZiaB?= NX\3Ulk5TE2VTx?= M4n6VmlEPTB;MD6wOFMh|ryP NUP2b|FsOjF2NEi1PVE>
CHLA-90 NGLIVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rtWlExKM7:TR?= MVy5OkBp MmXISG1UVw>? NWq4TZY1UUN3ME2wMlA3OSEQvF2= MoLzNlE1PDh3OUG=
CHLA-119 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrLbFA6OTBizszN M2fQelk3KGh? NVn3bHBFTE2VTx?= NGTUTnpKSzVyPUCuNFIzKM7:TR?= MljBNlE1PDh3OUG=
CHLA-122 NH;UWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPEU21rOTBizszN NGPIUlc6PiCq MmfjSG1UVw>? NYfs[oR{UUN3ME2wMlAyQSEQvF2= NYOwXopPOjF2NEi1PVE>
CHLA-136 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ENVAh|ryP NVfvTpRyQTZiaB?= NHrwe|lFVVOR MVfJR|UxRTBwMEO5JO69VQ>? M17YPVIyPDR6NUmx
CHLA-140 M2HS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNEDPxE1? M4HyPVk3KGh? NVfnW|NUTE2VTx?= NILUcndKSzVyPUCuNFI3KM7:TR?= NXXIXo53OjF2NEi1PVE>
LA-N-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexNEDPxE1? MnvlPVYhcA>? NYD3WIg5TE2VTx?= MVjJR|UxRTBwMEW0JO69VQ>? NWHsWIQ2OjF2NEi1PVE>
NB-1643 NHTnb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XEXVExKM7:TR?= NUPUOmxZQTZiaB?= NET2TYJFVVOR MYTJR|UxRTBwMEO3JO69VQ>? NFK1SpUzOTR2OEW5NS=>
NB-EBc1 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP3T5UyOCEQvF2= NIL3ZWU6PiCq MUXEUXNQ M3P6PGlEPTB;MD6wOVAh|ryP Ml:wNlE1PDh3OUG=
SK-N-BE-1 NF\qZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? MoLXPVYhcA>? Mnu4SG1UVw>? NVj3eYVwUUN3ME2wMlAzQCEQvF2= MXmyNVQ1QDV7MR?=
SK-N-BE-2 M3zlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PtblExKM7:TR?= NF\NdlA6PiCq NXfO[YdvTE2VTx?= MnLoTWM2OD1yLkCzOkDPxE1? NGrRW4szOTR2OEW5NS=>
SMS-KAN M2PJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmxNEDPxE1? MXy5OkBp MkXpSG1UVw>? NVe0OJdrUUN3ME2wMlA{PCEQvF2= NEfEUGMzOTR2OEW5NS=>
SMS-KANR M4LzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCxS457OTBizszN M4rMeVk3KGh? NHjPeJFFVVOR M2\tc2lEPTB;MD6wNlYh|ryP MX[yNVQ1QDV7MR?=
SMS-KCN MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? MXW5OkBp MVXEUXNQ MlvrTWM2OD1yLkCxPUDPxE1? M2\YV|IyPDR6NUmx
SMS-KCNR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174V|ExKM7:TR?= MVG5OkBp MYLEUXNQ NVTMXVFQUUN3ME2wMlAyOCEQvF2= M2TwcFIyPDR6NUmx
SMS-LHN Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWyNVAh|ryP NHLGRpc6PiCq MV3EUXNQ NWnmc453UUN3ME2wMlA{OiEQvF2= MkH0NlE1PDh3OUG=
SMS-MSN NV35NpozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf5NVAh|ryP MXq5OkBp NWPD[WhZTE2VTx?= Mk[4TWM2OD1yLkCyNkDPxE1? M{fqb|IyPDR6NUmx
SMS-SAN M1vCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjxXW4yOCEQvF2= NFTub3I6PiCq NH;NS2ZFVVOR MYnJR|UxRTBwMEKwJO69VQ>? NHS0fWQzOTR2OEW5NS=>
Granta-4 MofxR5l1d3SxeHnjJGF{e2G7 M37IOlExKM7:TR?= NXnOOmFMPyCm MYrJR|UxRTBwMESwJO69VQ>? NYHYbGZIOjF{OUG4Olc>
DB MofZR5l1d3SxeHnjJGF{e2G7 MXixNEDPxE1? NXnRc2tSPyCm MUfJR|UxRTBwMESyJO69VQ>? MlfWNlEzQTF6Nke=
RL NE[5O4NEgXSxdH;4bYMhSXO|YYm= M{XhNVExKM7:TR?= MWm3JIQ> MmPQTWM2OD1yLkCxOUDPxE1? NIjsTZgzOTJ7MUi2Oy=>
K562 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnjRnhHOTBizszN MlXiPVYhcA>? NVK1d4I4UUN3ME2wMlA5PyEQvF2= NEjMeo8zOTB7MU[zNy=>
LAMA-84 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m5NFExKM7:TR?= MXW5OkBp M{K5WGlEPTB;MD6wOVch|ryP MWSyNVA6OTZ|Mx?=
MM15 NVXqb4k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPiOEDPxE1? NEO3UZo4OiCq MX;EUXNQ M3qzfmlEPTB;MD6xN{DPxE1? MWSyNFM5Ojh2NB?=
OPM1 NYfIb5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzuOEDPxE1? M36yNFczKGh? M{HsUWROW09? NXW3Wo4{UUN3ME2wMlA{KM7:TR?= NIPkbWozODN6Mki0OC=>
RPM1 NH:1Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEixWYU1KM7:TR?= M1XhOFczKGh? MoX6SG1UVw>? M1PDS2lEPTB;MUCuN|Ih|ryP NU\HfmQ6OjB|OEK4OFQ>
INA6 NU\HZ3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfhOEDPxE1? NUnRUHlVPzJiaB?= Mlj0SG1UVw>? MmfVTWM2OD1yLkCwNkDPxE1? M4nXOFIxOzh{OES0
OPM2 M3vzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLGPXJCPCEQvF2= NV;ETos5PzJiaB?= MYLEUXNQ NH7EdYZKSzVyPUSuN|ch|ryP MmfVNlA{QDJ6NES=
MM1R M3fZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDFOEDPxE1? Ml31O|IhcA>? MWDEUXNQ MV7JR|UxRTFwNkig{txO MWqyNFM5Ojh2NB?=
DOX40 NUH2WJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PsdlQh|ryP M3\2VVczKGh? Mo\aSG1UVw>? MVvJR|UxRTVwNEig{txO MkTMNlA{QDJ6NES=
LR5 NETBTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rqZlQh|ryP NVeySZJJPzJiaB?= MkLlSG1UVw>? MnTYTWM2OD1{LkWzJO69VQ>? NHntVFEzODN6Mki0OC=>
U266 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW0JO69VQ>? M2P5blczKGh? M3\ycGROW09? MoT1TWM2OD1zLkSzJO69VQ>? MnL1NlA{QDJ6NES=
RD M2HxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNEDPxE1? M{fkdVk3KGh? Mnq0TWM2OD1yLkKyPEDPxE1? MW[yNFExQDN|OB?=
Rh41 NW\6N4lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljONVAh|ryP M2e3VFk3KGh? NHjWbFRKSzVyPUCuNFkxKM7:TR?= NE[3OFUzODFyOEOzPC=>
Rh30 NFXZdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnCPVUyOCEQvF2= NXzwZ5VYQTZiaB?= NGfCWIxKSzVyPUCuNlMxKM7:TR?= MWWyNFExQDN|OB?=
BT-12 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5NVAh|ryP MnfLPVYhcA>? Ml3UTWM2OD1yLkC2NEDPxE1? MVmyNFExQDN|OB?=
CHLA-266 NF25VodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFNVAh|ryP M{T2VFk3KGh? NWjve|dlUUN3ME2wMlA4OiEQvF2= M3rWbFIxOTB6M{O4
TC-71 NVu1fo94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xNEDPxE1? MU[5OkBp M2TKTWlEPTB;MD6xNFIh|ryP MkPtNlAyODh|M{i=
SJ-GBM2 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnzPJlTOTBizszN MX:5OkBp NIPPXGdKSzVyPUCuNFUxKM7:TR?= NXnYV2hPOjBzMEizN|g>
NALM-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNEDPxE1? M3rWdVk3KGh? MVHJR|UxRTBwME[yJO69VQ>? NIDhe|czODFyOEOzPC=>
COG-LL-317 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF61THcyOCEQvF2= NILqeJM6PiCq NX\Tfoh7UUN3ME2wMlA1PyEQvF2= MlrNNlAyODh|M{i=
RS4-11 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\jbmplOTBizszN MlrJPVYhcA>? MVjJR|UxRTBwMEG4JO69VQ>? MWOyNFExQDN|OB?=
MOLT-4 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL1NllOOTBizszN NHXOWXc6PiCq NX3Le|ZjUUN3ME2wMlAzPiEQvF2= M{XKPVIxOTB6M{O4
CCRF-CEM MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXObFUyOCEQvF2= NYjRZ2JQQTZiaB?= MXjJR|UxRTBwMEm0JO69VQ>? MoXtNlAyODh|M{i=
Kasumi-1 MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\D[ZAyOCEQvF2= NELWZng6PiCq MoG5TWM2OD1yLkGwN{DPxE1? MXqyNFExQDN|OB?=
Karpas-299 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxc25iOTBizszN NIPlOYo6PiCq NIXIZ4pKSzVyPUCuNFM5KM7:TR?= MnjtNlAyODh|M{i=
Ramos-RA1 M4fRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDVbngyOCEQvF2= M4HI[Fk3KGh? NFTnWXJKSzVyPUCuNVI4KM7:TR?= NUfETHVVOjBzMEizN|g>

... Click to View More Cell Line Experimental Data

In vivo試験 MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
細胞アッセイ: [2]
+ 展開
  • 細胞株: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 24, 48, and 72 hours
  • 実験の流れ: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (参考用のみ)
動物実験:[2]
+ 展開
  • 動物モデル: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • 製剤: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • 投薬量: ~30 mg/kg/day
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 15% Captisol 30 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 518.92
化学式

C27H20ClFN4O4

CAS No. 1028486-01-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase信号経路図

Aurora Kinase Inhibitors with Unique Features

相関Aurora Kinase製品

Tags: Alisertib (MLN8237)を買う | Alisertib (MLN8237) ic50 | Alisertib (MLN8237)供給者 | Alisertib (MLN8237)を購入する | Alisertib (MLN8237)費用 | Alisertib (MLN8237)生産者 | オーダーAlisertib (MLN8237) | Alisertib (MLN8237)化学構造 | Alisertib (MLN8237)分子量 | Alisertib (MLN8237)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID